C12N 2795/18011
Ssrna bacteriophages positive-sense
Official title: ssRNA Bacteriophages positive-sense
C12N2795/18011 (Ssrna bacteriophages positive-sense) appears on 103 US grants and 204 published applications in this corpus.
Search patents in C12N- Granted patents
- 103
- Published applications
- 204
- Assignees
- 93
- Inventors
- 363
- Latest grant
- 28 Jul 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1988 | 1 | 0 |
| 1989 | 0 | 0 |
| 1990 | 0 | 0 |
| 1991 | 0 | 0 |
| 1992 | 0 | 0 |
| 1993 | 1 | 0 |
| 1994 | 0 | 0 |
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 1 | 0 |
| 1999 | 2 | 0 |
| 2000 | 3 | 0 |
| 2001 | 4 | 0 |
| 2002 | 4 | 5 |
| 2003 | 1 | 5 |
| 2004 | 0 | 4 |
| 2005 | 1 | 2 |
| 2006 | 6 | 5 |
| 2007 | 1 | 8 |
| 2008 | 2 | 3 |
| 2009 | 3 | 4 |
| 2010 | 2 | 10 |
| 2011 | 2 | 10 |
| 2012 | 1 | 9 |
| 2013 | 3 | 5 |
| 2014 | 2 | 8 |
| 2015 | 1 | 5 |
| 2016 | 7 | 9 |
| 2017 | 5 | 4 |
| 2018 | 5 | 10 |
| 2019 | 4 | 7 |
| 2020 | 5 | 8 |
| 2021 | 3 | 14 |
| 2022 | 3 | 14 |
| 2023 | 7 | 8 |
| 2024 | 10 | 16 |
| 2025 | 3 | 20 |
| 2026 | 4 | 11 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Subgroups
Granted patents
- C12N 2795/18111LeviviridaeIndexing code94
- C12N 2795/18022New viral proteins or individual genes, new structural or functional aspects ofIndexing code7
- C12N 2795/18023Virus like particles [vlp]Indexing code4
- C12N 2795/18033Use of viral protein as therapeutic agent other than vaccineIndexing code3
- C12N 2795/18041Use of virus, viral particle or viral elements as a vectorIndexing code1
- C12N 2795/18051Methods of production or purification of viral materialIndexing code1
- C12N 2795/18071Demonstrated in vivo effectIndexing code1
- C12N 2795/18021Viruses as suchIndexing code0
All 13 subgroupsShow fewer
- C12N 2795/18031Uses of virus other than therapeutic or vaccineIndexing code0
- C12N 2795/18032Use of virus as therapeutic agent, other than vaccineIndexing code0
- C12N 2795/18034Use of virus or viral component as vaccineIndexing code0
- C12N 2795/18061Methods of inactivation or attenuationIndexing code0
- C12N 2795/18088For redistributionIndexing code0
Recent patents
- Methods and compositions for microbial delivery of double stranded RNA28 Jul 2026US 12,690,596 B2Rnaissance AG LLC
- Mutant myocilin disease model and uses thereof24 Mar 2026US 12,582,104 B2Regeneron Pharmaceuticals, Inc.
- Cells for enhanced production of adeno-associated virus17 Mar 2026US 12,577,539 B2The Regents of the University of California
- Compositions and methods for controlled mRNA translation and stability3 Mar 2026US 12,565,665 B2Trustees of Boston University
- Lentiviral-based vectors and related systems and methods for eukaryotic gene editing26 Aug 2025US 12,398,182 B2Wake Forest University Health Sciences
- Methods and compositions for microbial delivery of double stranded rna8 Oct 2026US 2026/0305618 A1Rnaissance AG LLC
- Method for controlling intracellular localization of sgrna and regulating gene expression24 Sep 2026US 2026/0286351 A1Guangzhou Medical University
- Sialokinin immunogen and methods for using same13 Aug 2026US 2026/0234184 A1
- System for regulating protein translation13 Aug 2026US 2026/0234645 A1National University Corporation Tokyo Medical and Dental University
- Compositions and methods of genome editing23 Jul 2026US 2026/0209730 A1Epigenic Therapeutics Pte. Ltd.
Most cited
By later US patents
- Autocatalytic replication of recombinant RNA181US 4,786,600 AThe Trustees of Columbia University in the City of New York · 1988
- Ribonuclease resistant RNA preparation and utilization80US 5,939,262 AAmbion, Inc. · 1999
- Hapten-carrier conjugates and uses thereof75US 6,932,971 B2Cytos Biotechnology AG · 2005
- Method for inactivating pathogens in red cell compositions using quinacrine mustard63US 5,691,132 ACerus Corporation · 1997
- Treating red blood cell solutions with anti-viral agents57US 5,559,250 ASteritech, Inc. · 1996